These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 1831083)
1. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers. Burnier M; Ganslmayer M; Perret F; Porchet M; Kosoglou T; Gould A; Nussberger J; Waeber B; Brunner HR Clin Pharmacol Ther; 1991 Aug; 50(2):181-91. PubMed ID: 1831083 [TBL] [Abstract][Full Text] [Related]
2. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735 [TBL] [Abstract][Full Text] [Related]
3. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor. Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404 [TBL] [Abstract][Full Text] [Related]
4. Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand. Kukkonen P; Vuolteenaho O; Ruskoaho H Endocrinology; 1992 Feb; 130(2):755-65. PubMed ID: 1531129 [TBL] [Abstract][Full Text] [Related]
5. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats. Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942 [TBL] [Abstract][Full Text] [Related]
6. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774 [TBL] [Abstract][Full Text] [Related]
7. Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. Sybertz EJ; Chiu PJ; Watkins RW; Vemulapalli S Can J Physiol Pharmacol; 1991 Oct; 69(10):1628-35. PubMed ID: 1838029 [TBL] [Abstract][Full Text] [Related]
8. Elevation of plasma atrial natriuretic peptide in rats with chronic heart failure by SCH 39370, a neutral metalloendopeptidase inhibitor. Tikkanen I; Helin K; Tikkanen T; Sybertz EJ; Vemulapalli S; Sariola H; Näveri H; Fyhrquist F J Pharmacol Exp Ther; 1990 Aug; 254(2):641-5. PubMed ID: 2143536 [TBL] [Abstract][Full Text] [Related]
9. Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects. Helin K Scand J Clin Lab Invest; 1993 Dec; 53(8):843-51. PubMed ID: 8140395 [TBL] [Abstract][Full Text] [Related]
10. Hemodynamic and hormonal effects of neutral endopeptidase inhibitor SCH 39370 in sheep. Charles CJ; Espiner EA; Cameron VA; Richards AM; Yandle TG; Sybertz EJ Hypertension; 1991 May; 17(5):643-51. PubMed ID: 1850715 [TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats. Sala C; Monopoli A; Casati C; Ardeleani G; Ongini E; Zanchetti A; Morganti A J Cardiovasc Pharmacol; 1994 May; 23(5):703-8. PubMed ID: 7521451 [TBL] [Abstract][Full Text] [Related]